pharmaphorum

NOVEMBER 16, 2022

Having presented the data from the 24-month phase 3 trial at the American Academy of Ophthalmology (AAO) annual meeting, Dr Wykoff set aside some time to go into further detail with pharmaphorum about how the results were received, and what glimmer of hope this might hold for patients with GA.

Genetics 105

Genetics Trials Clinical Trials Clinical Trials 105

XTalks

MARCH 7, 2024

Experts discuss the therapeutic landscape, treatment gaps, regulatory considerations and clinical trial strategies. The webinar provides insights into a novel method that facilitates detailed genetic analysis of breast cancer, marrying the depth of whole-genome studies with the precision of targeted analysis at the single-cell level.

Genetics 115

Genetics Hormones Genomics Genome 115

FDA Law Blog

MARCH 13, 2023

Who better than people living with a condition to inform drug companies, physicians, academics, and the FDA on what it is like to live with their condition, what symptoms most impact their lives, what goes into their decision about whether to participate in a clinical trial, and what kind of treatment effects would be most meaningful to them?

Gene Therapy 98

Gene Therapy Gene Trials Clinical Trials 98

The Pharma Data

SEPTEMBER 3, 2020

Comparing four separate forms of the disease, they found that samples of the most aggressive form, known as metastases-like primary tumours, saw changes in activity of 74 immune-related genes, compared with changes in only 12 in the more benign insulinoma-like tumours. Source link.

Research 52

Research Genetic Analysis Gene Scientist 52

The Pharma Data

APRIL 8, 2022

Data from the research were recently included in the company’s Investigational New Drug (IND) application to the FDA to initiate a Phase 2 clinical trial for COVID-19. Based on these studies, one of those drugs was licensed to Cantex Pharmaceuticals for the treatment of COVID-19 and other inflammatory lung diseases.

Immune Response 52

Immune Response In-Vivo Genetic Analysis Research 52

XTalks

JANUARY 6, 2025

For example, antisense oligonucleotide (ASO)-based therapies have gained traction, with 100 Phase I clinical trials initiated and around 25 percent of these advancing to Phase II or Phase III trials in recent years. Furthermore, CRISPR/Cas9 presents a promising avenue for overcoming genetic diseases in the near future.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111